FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape.

Samuel J KlempnerRussell MadisonVivek PujaraJeffrey S RossVincent A MillerSiraj M AliAlexa B SchrockSeung Tae KimSteven B Maron Farshid Dayyani Daniel V T CatenacciJeeyun LeeJoseph Chao

Published in: The oncologist (2019)

Actionable receptor tyrosine kinase alterations assayed within a genomic context with therapeutic implications remain limited to HER2 amplification in gastroesophageal adenocarcinomas (GEA). Composite biomarkers and heterogeneity assessment are critical in optimizing patients selected for targeted therapies in GEA. Comprehensive genomic profiling in FGFR2-altered GEA parallels the heterogeneity findings in HER2-amplified GEA and adds support to the utility of genomic profiling in advanced gastroesophageal adenocarcinomas.

Keyphrases

single cell
tyrosine kinase
copy number
end stage renal disease
epidermal growth factor receptor
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
dna methylation
gene expression
genome wide
binding protein